Alzheimer's Disease Clinical Research Trials

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Sun City : Banner Sun Health Research Institute

A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety,and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patients with Alzheimer’s disease.

Sun City : Banner Sun Health Research Institute

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease

Sun City : Banner Sun Health Research Institute

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline

Sun City : Banner Sun Health Research Institute

ADvance: A 12-month double-blind, randomized, controlled feasibility study to evaluate the safety, efficacy and tolerability of deep brain stimulation of the fornix (DBS-f) in patients with mild probable Alzheimer’s disease

Sun City : Banner Sun Health Research Institute

Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)

Sun City : Banner Sun Health Research Institute

Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease

Goodyear : Call for Information (Investigational Site 0002)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Phoenix :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Phoenix : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Phoenix : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Phoenix :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Phoenix : Barrow Neurological Institute

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

Phoenix :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Scottsdale : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Sun City : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Sun City : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Sun City :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Sun City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Tucson : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Fayetteville : Call for Information (Investigational Site 0047)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Encino : Pharmacology Research Institute, Encino

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease

Encino : Pharmacology Research Institute, Encino

Study of an investigational medication for the treatment of Alzheimer's Disease

Glendale : California Clinical Trials Medical Group, Inc.

Alzheimer's Disease Study

Los Alamitos : Pharmacology Research Institute, Los Alamitos

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease

Los Alamitos : Pharmacology Research Institute, Los Alamitos

Study of an investigational medication for the treatment of Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for mild to moderate Alzheimer's Disease

Newport Beach : Pharmacology Research Institute, Newport Beach

Study of an investigational medication for the treatment of Alzheimer's Disease

Sacramento : Sutter Institute for Medical Research (SIMR)

Mild Cognitive Impairment

Santa Ana : Apex Research Institute

Alzheimers? Be a Part of Research.

Santa Rosa : Radiant Research - Santa Rosa

Alzheimer's Disease Research Study

Sherman Oaks : California Neuroscience Research Medical Group, Inc.

Clinical research study of an investigational medication vs. placebo for agitation in persons with Alzheimer’s disease.

Sherman Oaks : Schuster Medical Research Institute

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease.

Aliso Viejo : Avanir Pharmaceuticals

PRISM Registry: Pseudobulbar Affect Registry Series

Costa Mesa : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Encino : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Escondido : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Escondido :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Fountain Valley : Call for Information (Investigational Site 0050)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Fountain Valley :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Fresno :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Fresno : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Fresno :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Fullerton : Call for Information (Investigational Site 0079)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Glendale : California Clinical Trials Medical Group, Inc.

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Glendale : Glendale Adventist Medical Center

Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease

Laguna Hills :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Lomita :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Long Beach :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Long Beach : Collaborative Neuroscience Network Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Long Beach : Call for Information (Investigational Site 0053)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Long Beach : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Long Beach : Site Reference ID/Investigator# 69602

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Long Beach :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Long Beach : Site Reference ID/Investigator# 84185

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Los Alamitos : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Los Angeles :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Sacramento : Call for Information (Investigational Site 0007)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

San Diego : Pacific Research Network Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

San Diego :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

San Diego :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

San Francisco :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

San Francisco : Site Reference ID/Investigator# 66527

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

San Francisco : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

San Francisco :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

San Francisco : Site Reference ID/Investigator# 84183

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

San Francisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Santa Ana : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Santa Monica :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Sherman Oaks :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Sherman Oaks :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Valencia : Sanguine Biosciences

A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery

Boulder : Alpine Clinical Research Center

New Investigational Medication for Autism, Asperger's Disorder, or Pervasive Developmental Disorder in Pediatric Patients (PDD-NOS)

Boulder : Alpine Clinical Research Center

New Investigational Medication for Mild Alzheimer's Disease

Denver : Radiant Research - Denver

Memory Loss Research Study

Boulder : Alpine Clinical Research Center Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Hamden : Site Reference ID/Investigator# 66530

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Hamden : Site Reference ID/Investigator# 84187

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Hamden : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

New Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Norwalk : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Norwich : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Waterbury : Chase Medical Research, LLC Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Washington : Call for Information (Investigational Site 0077)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Hallandale Beach : MD Clinical

Is your memory loss just a sign of age, or something else?

Miami : Research Site

Alzheimer’s Research Study ITN# 12038

Miami : Research Site

Alzheimer's Disease ITN# 12129

Miami : Research Site

Alzheimer's Disease ITN# 12160

Ocala : Renstar Medical Research

Alzheimer's Disease

St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL

Alzheimer’s Disease ITN# 12032

St. Petersburg : Meridien Research

Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida

A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension

Tampa : Axiom Clinical Research of Florida

A Phase Ii, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Investigate The Efficacy And Safety Of Ro4602522 Added To The Background Therapy Of The Acetylcholinesterase Inhibitors Donepezil Or Rivastigmine In Patients With Moderate Severity Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida

A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida

A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel Group Study Of The Safety And Efficacy Of PF-05212377 (SAM-760) In Subjects With Mild-To-Moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil

Tampa : Axiom Clinical Research of Florida

A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease

Atlantis : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Brooksville : Meridian Research Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Brooksville :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Brooksville : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Clearwater : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Deerfield Beach : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Deerfield Beach :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Deerfield Beach : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Delray Beach : Brain Matters Research Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Delray Beach : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 56503

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 66522

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Delray Beach : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Delray Beach :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 84178

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Delray Beach : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Delray Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Delray Beach : Site Reference ID/Investigator# 73493

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Fort Lauderdale : Call for Information (Investigational Site 0008)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Fort Myers :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Fort Myers : Neuropsychiatric Research Center of Southwest Florida Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Fort Myers : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Hallandale Beach :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Hallandale Beach : MD Clinical Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Hallandale Beach : Call for Information (Investigational Site 0059)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Hallandale Beach : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Hallandale Beach :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Hallandale Beach : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Hollywood : Call for Information (Investigational Site 0063)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Jacksonville :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Lake Worth : Alzheimer's Research and Treatment Center Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Lake Worth : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Miami : Miami Jewish Health Systems Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Miami : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Miami :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Miami :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Miami Beach : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Oakland Park : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Ocala : Call for Information (Investigational Site 0058)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Orlando :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Orlando : Compass Research, LLC Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Orlando : Call for Information (Investigational Site 0018)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Orlando : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Orlando : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Orlando : Site Reference ID/Investigator# 66524

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Orlando : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Orlando :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Orlando : Site Reference ID/Investigator# 84180

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Orlando : Compass Research

Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease

Ormond Beach : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Palm Beach Gardens : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Port Charlotte : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Sarasota : The Roskamp Institute Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Sarasota : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Sunrise : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Sunrise :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Tampa :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

Tampa : Axiom Clinical Research of Florida Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Tampa :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Tampa : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Tampa : Site Reference ID/Investigator# 84188

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Tampa : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

West Palm Beach : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

West Palm Beach :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

West Palm Beach : Site Reference ID/Investigator# 56514

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

West Palm Beach : Site Reference ID/Investigator# 66529

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

West Palm Beach : Site Reference ID/Investigator# 84186

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

West Palm Beach : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

West Palm Beach : Site Reference ID/Investigator# 73496

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Weston :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Atlanta : NeuroTrials Research

New Alzheimer’s Disease Research

Atlanta :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Atlanta : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Decatur :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Savannah : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Elk Grove Village : Alexian Brothers Hospital Network

A multinational, multicenter, randomized, double-blind, parallel-group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy

Elk Grove Village : Alexian Brothers Hospital Network

A phase 2 multicenter, double-blind, placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's Disease on stable Donepezil therapy.

Elk Grove Village : Alexian Brothers Hospital Network

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Subjects with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carriers

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Diseases

Chicago : Call for Information (Investigational Site 0064)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Chicago : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Elk Grove Village :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Elk Grove Village :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Elk Grove Village : Site Reference ID/Investigator# 62611

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Site Reference ID/Investigator# 66526

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Elk Grove Village :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Elk Grove Village : Site Reference ID/Investigator# 84182

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Elk Grove Village : Site Reference ID/Investigator# 73495

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Springfield : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Lexington : University of Kentucky Chandler Medical Center

Can Brain Waves Diagnose Alzheimer’s Disease?

Lexington : University of Kentucky Chandler Medical Center

Down Syndrome, Aging & Alzheimer's Disease Study

Lexington : University of Kentucky Chandler Medical Center

Turning off the Alzheimer switch!

Lexington : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Lake Charles : Lake Charles Clinical Trials

Study of PF-05212377 in Participants with Mild to Moderate Alzheimer's Disease with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

Lake Charles : Lake Charles Clinical Trials

Studying the Effects of Daily Administration of AC-1204 versus Placebo in People with Mild to Moderate Alzheimer's Disease (AD).

Baton Rouge : Call for Information (Investigational Site 0043)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Lake Charles : Lake Charles Clinical Trials Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Shreveport : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Bangor : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Baltimore : Call for Information (Investigational Site 0040)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Boston : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Boston : Beth Israel Deaconess Medical Center

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

Chestnut Hill : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Haverhill :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Plymouth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Quincy : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Quincy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Winchester : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Kalamazoo : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Hattiesburg : Hattiesburg Clinic Neurological Research Center

Mayflower: A phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to investigate the efficacy and safety of RO4602522 added to the background therapy of the acetylcholinesterase inhibitors Donepezil or Rivastigmine in patients with moderate severity Alzheimer’s Disease

Flowood : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Olive Branch :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Kansas City : Call for Information (Investigational Site 0025)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

St. Louis : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Las Vegas : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Las Vegas :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Stratford : University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine

Alzheimer's disease study for mild to moderate AD.

Eatontown : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Eatontown :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Manchester : Alzheimer's Research Corporation Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Monroe Township :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Monroe Township : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Princeton : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Summit : The Cognitive Research Center of New Jersey Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Summit :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Summit :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Toms River : Memory Enhancement Center of NJ Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Toms River : Call for Information (Investigational Site 0054)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Toms River :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Toms River : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Toms River :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

New Hyde Park : Parker Jewish Institute

This study will investigate the safety and efficacy of immune globulin intravenous, for the treatment of mild to moderate Alzheimer's Disease.

New York : The Rockefeller University Hospital

Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer’s Disease

New York : Biomedical Research Alliance of New York

People with Alzheimer’s disease are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.

Albany :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Brooklyn : SPRI Clinical Trials, LLC Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Brooklyn :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Manhasset : Call for Information (Investigational Site 1061)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Orangeburg :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Patchogue : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Rochester : Call for Information (Investigational Site 0039)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Rochester : Call for Information (Investigational Site 0089)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Rochester : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Rochester :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Staten Island : Site Reference ID/Investigator# 56506

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 66525

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Staten Island :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 84181

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Staten Island : Site Reference ID/Investigator# 73494

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Charlotte : PMG Research of Charlotte

Does your loved one with Alzheimer's Disease display aggression or agitation?

Greensboro : Guilford Neurologic Associates

Impact of Florbetapir F 18 PET on the Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

Raleigh : Multi-Specialty Research Associates of NC

Is Alzheimer’s Disease affecting your loved one?

Wilmington : PMG Research of Wilmington Updated

Does your loved one with Alzheimer’s Disease display aggression or agitation?

Winston-Salem : PMG Research of Winston-Salem

Do you care for someone afflicted with Alzheimer's Disease?

Winston-Salem : PMG Research of Winston-Salem

MEMORIES MATTER! Is Alzheimer's Disease taking away the enjoyment in your life?

Charlotte : Call for Information (Investigational Site 0013)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Charlotte : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Durham : Duke Health Center at Morreene Road

Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias

Durham : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Durham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Greensboro : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Raleigh : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Wilmington : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Winston-Salem : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Beachwood : Call for Information (Investigational Site 0033)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Beachwood : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Canton : Call for Information (Investigational Site 0010)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Canton :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Centerville :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Cincinnati : Community Research Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Cleveland :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Columbus :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Lakewood :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Toledo : Research Site

Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.

Oklahoma City : Call for Information (Investigational Site 0027)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Oklahoma City : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Oklahoma City :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Tulsa : Call for Information (Investigational Site 0055)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Portland : Summit Research Network (Oregon), Inc.

Alzheimer's Research Study

Portland : Summit Research Network (Oregon), Inc.

Are you questioning your memory?

Portland : Call for Information (Investigational Site 0067)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Portland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Abington : Call for Information (Investigational Site 0081)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Abington : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Jenkintown : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Jenkintown : Site Reference ID/Investigator# 82994

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Jenkintown :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Norristown : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Pittsburgh : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

East Providence :

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease

East Providence : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Providence : Call for Information (Investigational Site 0060)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Providence : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Greer : Radiant Research - Greer

Clinical Research Study for Alzheimer's Disease

North Charleston :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Port Royal : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Nashville : Clinical Research Associates, Inc.

Alzheimer's Disease Research Study

Cordova : Neurology Clinic, P.C. Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Cordova : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Kingsport : Call for Information (Investigational Site 0049)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Memphis : Clinical Neuroscience Solutions, Inc Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Memphis :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Nashville : Call for Information (Investigational Site 0045)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Dallas : Texas Neurology, PA

Alzheimer's Research Study

Dallas : Texas Neurology, PA

Mild Cognitive Impairment

Austin : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Dallas : Call for Information (Investigational Site 0076)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Dallas : Call for Information (Investigational Site 0074)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

DeSoto : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Houston :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

San Antonio :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

San Antonio : CEDRA Clinical Research, LLC

Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment

Wichita Falls : Site Reference ID/Investigator# 77636

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Salt Lake City : Lifetree Clinical Research

Alzheimer's Research Study

Salt Lake City : CRI Lifetree

Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease

Salt Lake City : Lifetree Clinical Research

Patients are defined as otherwise healthy males or females as determined by medical history, physical examination and a diagnosis of AD and must be at least 45 years of age.

Salt Lake City : Lifetree Clinical Research

Patients who have a diagnosis of probable AD and experience agitation.

Salt Lake City : Lifetree Clinical Research

Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease

Salt Lake City : Lifetree Clinical Research

Subjects with Mild Alzheimer's Disease

Salt Lake City : CRI Lifetree

The objectives of the study are to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with AD.

Salt Lake City : CRI Lifetree

To assess the safety, tolerability, and the effects of of BMS-241027 on CSF Tau Nterminal domain fragment in subjects with mild Alzheimer’s Disease (AD).

Salt Lake City : CRI Lifetree

To evaluate the effect of gantenerumab vs. placebo on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability

Murray : Call for Information (Investigational Site 0004)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Salt Lake City : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Salt Lake City :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Bennington : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Bennington :

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients

Bennington : Site Reference ID/Investigator# 56504

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Bennington : Site Reference ID/Investigator# 66523

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Bennington : Site Reference ID/Investigator# 84179

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Burlington : Fletcher Allen Health Care-Clinical Neuroscience Research Unit

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

Richmond : National Clinical Research - Richmond, Inc. Updated

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext

Richmond : Call for Information (Investigational Site 0062)

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Richmond : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Bellevue : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Richland : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Milwaukee : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Waukesha : Pfizer Investigational Site

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

Randwick : GSK Investigational Site

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers

Gatineau : Site Reference ID/Investigator# 71793

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Gatineau : Site Reference ID/Investigator# 84173

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Kelowna : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Kirkland : Merck Frosst Canada

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Medicine Hat :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Montreal : Site Reference ID/Investigator# 71794

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Peterborough : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Peterborough : Site Reference ID/Investigator# 71798

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Peterborough : Site Reference ID/Investigator# 84177

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Toronto :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toronto : Elan Investigational Site

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Toronto : Site Reference ID/Investigator# 71795

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Toronto : Site Reference ID/Investigator# 84175

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Verdun : Site Reference ID/Investigator# 71796

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Verdun : Site Reference ID/Investigator# 84176

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Baoding : Hebei mental health center

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Novartis Investigative Site

A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease

Beijing : Peking University Institute of Mental Health

Memantine on Aggression and Agitation of Alzheimer's Disease (AD)

Beijing : Beijing Shijitan Hospital, EMU

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Beijing : Beijing HuiLongGuan Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Changchun : The first Affiliated Hospital of Jilin University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guangzhou : Guangzhou Brain Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Guilin : Affiliated Hospital of Guilin Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Hangzhou : The First Affiliated Hospital of Medical School of Zhejiang University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Kunming : First Affiliated Hospital of Kunming Medical University

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Nanjing : Jiangsu Province Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Mental Health Center

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Changzheng Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai First People's Hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Shanghai : Shanghai Tenth People's hospital

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Turku :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

Aix En Provence : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Bordeaux :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Caen : CHU de la Côte de Nacre

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Cahors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Castres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Clermont-Ferrand : CHU Clermont-Ferrand

Alzheimer and Sleep

Dijon Cedex : Site Reference ID/Investigator# 71573

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Foix Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lavaur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Léon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Limoges : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Limoges Cedex : Site Reference ID/Investigator# 77833

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Limoges Cedex : Site Reference ID/Investigator# 84373

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Marseille : Hôpital Sainte-Marguerite

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Montauban Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Montpellier cedex : CHU Gui de Chauliac

Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers

Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Nantes : Hôpital Guillaume et René Laennec

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Nice :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Nice : Hôpital de l'Archet

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Nice : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Paris :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Paris :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Paris : MSD France

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Paris : Pitié-Salpêtrière Hospital

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Pitié-Salpêtrière Hospital - Fédération de Neurologie

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Paris : Site Reference ID/Investigator# 68706

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Paris Cedex 10 : Site Reference ID/Investigator# 68704

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Paris Cedex 10 : Site Reference ID/Investigator# 84374

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Pierre Bénite : Investigational Site Number 250001 Updated

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Rennes : Hôpital Pontchaillou

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Rouen : Hôpital Charles Nicolle

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Brieuc : Centre Hospitalier

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Saint-Etienne : Hôpital Bellevue

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Strasbourg : Hôpital Civil

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Toulouse :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Toulouse :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Toulouse : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Toulouse Cedex 9 : Site Reference ID/Investigator# 68705

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Tours Cedex 9 :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Vic-En-Bigorre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Non-drug Methods Study in Patients With Alzheimer's Disease

Berlin :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Berlin : Site Reference ID/Investigator# 68768

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Berlin : Site Reference ID/Investigator# 84382

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Erlangen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Frankfurt :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Freiburg : Site Reference ID/Investigator# 68764

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Freiburg : Site Reference ID/Investigator# 84380

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Huettenberg : Site Reference ID/Investigator# 68767

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Huettenberg : Site Reference ID/Investigator# 84383

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Mittweida : Site Reference ID/Investigator# 69960

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Mittweida : Site Reference ID/Investigator# 84379

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Muenchen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Munich : Site Reference ID/Investigator# 68765

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Munich : Site Reference ID/Investigator# 84381

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Schwerin : Site Reference ID/Investigator# 69959

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Schwerin : Site Reference ID/Investigator# 84378

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Siegen :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Athens : Site Reference ID/Investigator# 68730

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Athens : Site Reference ID/Investigator# 68732

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Athens : Site Reference ID/Investigator# 68733

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Athens : Site Reference ID/Investigator# 84385

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Athens : Site Reference ID/Investigator# 84388

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Haidari, Athens : Site Reference ID/Investigator# 68731

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Haidari, Athens : Site Reference ID/Investigator# 84386

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Thessaloniki : Site Reference ID/Investigator# 68735

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Thessaloniki : Site Reference ID/Investigator# 68729

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Tel Aviv : Merchav Clinics

Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease

Tel Aviv : Tel Aviv Sourasky Medical Center, Neurology Department

Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease

Bergamo : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Genoa : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Milan : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Pisa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Rome : Research Site

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Rome : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Anjo-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Azumino-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Chiyoda-Ku, Tokyo : MSD K.K.

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Fukui-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Fukuoka-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Fukuoka-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Hachioji-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kamakura-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kamakura-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kansai : Kansai region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Kanto : Kanto region,

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Kanto :

Safety and Efficacy of MT-4666

Kasukabe-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kawasaki-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kawasaki-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kita-gun : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kitamorokata-gun : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Koshi-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Koshi-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Koshigaya-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kumamoto City : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kyoto : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kyoto-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Kyoto-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Kyushu : Kyushu region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Miyoshi-city : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Miyoshi-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Musashino-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Nagoya : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Ohtake : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Sagamihara : Pfizer Investigational Site Updated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Sapporo-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Setagaya-ku : Pfizer Investigational Site Updated

Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease

Suita-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Toakai : Tokai region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Tohoku : Tohoku region

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients

Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Toon-city : Novartis Investigative Site

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

Yokohama : Novartis Investigative Site

Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors

Daejeon : Chungnam national university hospital, Daejeon Geriatric Medical Center

Effect of NeuroAD on Alzheimer Patients

Goyang : National Health Insurance Corporation Ilsan Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Incheon : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Seoul : SKChemicals invetigational site

A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease

Seoul : Samsung Medical Center

Clinical Trial of Donepezil Between the Naive Group and the Switching Group

Seoul : Pfizer Investigational Site

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Seoul : The Catholic University of Korea, Seoul St. Mary's Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Seoul : Kyung Hee University Oriental Medicine Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Seoul City : Samsung Medical Center

Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia

Suwon : The Catholic University of Korea, St. Vincent's Hospital

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

Amsterdam : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Haarlem : Merck Sharp & Dohme BV

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Leiden : Investigational Site Number 528001 Updated

Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients

Wellington : Merck Sharp & Dohme (New Zealand) Ltd.,

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Gdynia : Site Reference ID/Investigator# 62565

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Gdynia : Site Reference ID/Investigator# 73513

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Poznan : Site Reference ID/Investigator# 62563

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Poznan : Site Reference ID/Investigator# 73514

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Szczecin : Site Reference ID/Investigator# 62562

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Szczecin : Site Reference ID/Investigator# 73515

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Kazan : Site Reference ID/Investigator# 60955

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kazan : Site Reference ID/Investigator# 60945

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kazan : Site Reference ID/Investigator# 73516

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Kazan : Site Reference ID/Investigator# 73525

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Kirov : Site Reference ID/Investigator# 60954

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kirov : Site Reference ID/Investigator# 73523

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Moscow : Site Reference ID/Investigator# 60959

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Moscow : Site Reference ID/Investigator# 60951

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Moscow : Site Reference ID/Investigator# 73521

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Novosibirsk : Site Reference ID/Investigator# 60946

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Novosibirsk : Site Reference ID/Investigator# 73517

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Saratov : Site Reference ID/Investigator# 60950

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Saratov : Site Reference ID/Investigator# 73520

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

St. Petersburg : Site Reference ID/Investigator# 60947

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60949

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60952

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 60958

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

St. Petersburg : Site Reference ID/Investigator# 73524

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

St. Petersburg : Site Reference ID/Investigator# 73522

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

St. Petersburg : Site Reference ID/Investigator# 73518

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

St. Petersburg : Site Reference ID/Investigator# 84615

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Belville : Site Reference ID/Investigator# 60911

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Belville : Site Reference ID/Investigator# 67586

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Belville : Site Reference ID/Investigator# 73507

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Cape Town : Site Reference ID/Investigator# 76073

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Cape Town : Site Reference ID/Investigator# 67582

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Cape Town : Site Reference ID/Investigator# 84391

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

George : Site Reference ID/Investigator# 60912

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

George : Site Reference ID/Investigator# 67584

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

George : Site Reference ID/Investigator# 84393

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

George : Site Reference ID/Investigator# 73505

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Johannesburg : Site Reference ID/Investigator# 60910

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Johannesburg : Site Reference ID/Investigator# 67585

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Johannesburg : Site Reference ID/Investigator# 84394

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Johannesburg : Site Reference ID/Investigator# 73506

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Rosebank : Site Reference ID/Investigator# 67583

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Barcelona : Funcació ACE

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Barcelona :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Barcelona :

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

Elche :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Getafe : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Granada : Department of Biochemistry and Molecular Biology II. University of Granada

Evaluation of a Diet in Patients With Senile Dementia

Granada : Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves

Evaluation of a Diet in Patients With Senile Dementia

Madrid :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Madrid : Merck Sharp and Dohme de Espana S.A.

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

Sant Cugal Del Valles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease

Sevilla :

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Donetsk : Site Reference ID/Investigator# 60909

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Donetsk : Site Reference ID/Investigator# 73533

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Kiev : Site Reference ID/Investigator# 60906

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Kiev : Site Reference ID/Investigator# 73534

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Poltava : Site Reference ID/Investigator# 60905

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Poltava : Site Reference ID/Investigator# 73535

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Bath : Site Reference ID/Investigator# 60960

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Bath : Site Reference ID/Investigator# 67787

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Bath : Site Reference ID/Investigator# 84398

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Bath : Site Reference ID/Investigator# 73502

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Blackburn : Site Reference ID/Investigator# 60963

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Blackburn : Site Reference ID/Investigator# 73503

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Blackpool :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Bradford :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Cambridge : GSK Investigational Site

Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects

Cannock :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Glasgow : Site Reference ID/Investigator# 60962

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

Glasgow : Site Reference ID/Investigator# 67784

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Glasgow : Site Reference ID/Investigator# 84397

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Glasgow : Site Reference ID/Investigator# 73501

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Hoddesdon : Merck Sharp & Dohme Ltd.

An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)

London : Site Reference ID/Investigator# 60961

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease

London : Site Reference ID/Investigator# 67786

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

London : Site Reference ID/Investigator# 84400

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

London : Site Reference ID/Investigator# 73504

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.

Manchester : Site Reference ID/Investigator# 67785

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Manchester :

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

Manchester : Site Reference ID/Investigator# 84399

Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Southampton : Memory Assessment and Research Centre, Moorgreen Hospital

Safety and Tolerability of Etanercept in Alzheimer's Disease

Warrington : Site Reference ID/Investigator# 67783

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease Clinical Trials

Alabama

Arizona

Arkansas

California

Colorado

Connecticut

District of Columbia

Florida

Georgia

Illinois

Kentucky

Louisiana

Maine

Maryland

Massachusetts

Michigan

Mississippi

Missouri

Nevada

New Jersey

New York

North Carolina

Ohio

Oklahoma

Oregon

Pennsylvania

Rhode Island

South Carolina

Tennessee

Texas

Utah

Vermont

Virginia

Washington

Wisconsin

Australia

Canada

China

Finland

France

Germany

Greece

Israel

Italy

Japan

Korea, Republic of

Netherlands

New Zealand

Poland

Russian Federation

South Africa

Spain

Ukraine

United Kingdom